论文部分内容阅读
Objective: To detect K-ras mutations to predict the efficacy of EGFR-TK inhibitor cetuximab treatment on Chinese patients with metastatic colorectal cancer (mCRC).Methods: Eighty-seven patients with metastatic colorectal cancer were treated with cetuximab for 2 months to 16 months,in combination with chemotherapy, between August 2010 and July 2012.Tissue samples were used to detect K-ras mutations.